Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560035 | 0.90 | HRH3 (0.49) | HRH3PIK3CD | |
| SCHEMBL24608232 | 0.85 | HRH3 (0.45) | HRH3PIK3CD | |
| SCHEMBL23134534 | 0.83 | HRH3 (0.48) | HRH3PIK3CD | |
| SCHEMBL22794102 | 0.83 | HRH3 (0.44) | HRH3PIK3CD | |
| SCHEMBL23560049 | 0.83 | HRH3 (0.44) | HRH3PIK3CD | |
| SCHEMBL23153725 | 0.82 | PIK3CD (0.39) | HRH3PIK3CD | |
| SCHEMBL25468591 | 0.82 | HRH3 (0.42) | HRH3PIK3CD | |
| SCHEMBL23568927 | 0.81 | HRH3 (0.43) | HRH3PIK3CD | |
| SCHEMBL24764631 | 0.80 | HRH3 (0.46) | HRH3PIK3CD | |
| SCHEMBL23695845 | 0.80 | HRH3 (0.42) | HRH3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1734/4885PIK3CD 2371/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1490/4885PIK3CD 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.